Physician profile
Devanshi Mehta
NPI 1831576784
$842.84
in general payments reported to CMS, 2019-2025
13 companies · $824 in 2025
The $824 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $18.64 · 2025: $824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $842.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $225.36 | 2025 | Trelegy Ellipta, Nucala |
| Insmed, INC. | $217.40 | 2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $84.18 | 2025 | |
| Merck Sharp & Dohme LLC | $66.68 | 2023-2025 | Capvaxive, Pifeltro, Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.92 | 2025 | Jascayd |
| Astrazeneca Pharmaceuticals Lp | $35.95 | 2025 | Airsupra |
| Paratek Pharmaceuticals, INC. | $34.61 | 2025 | Nuzyra |
| Electromed, INC. | $29.58 | 2025 | Smartvest |
| United Therapeutics Corporation | $22.47 | 2025 | Tyvaso |
| Harmony Biosciences LLC | $19.07 | 2025 | |
| Philips North America LLC | $17.20 | 2025 | Vest Therapy Und |
| Amgen INC. | $16.51 | 2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $14.91 | 2025 | Glassia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devanshi Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.